178 related articles for article (PubMed ID: 35175496)
1. HHLA2 Activates the JAK/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells.
Guo H; Zhang C; Tang X; Zhang T; Liu Y; Yu H; Li Y; Wang R
Inflammation; 2022 Aug; 45(4):1585-1599. PubMed ID: 35175496
[TBL] [Abstract][Full Text] [Related]
2. SRRM1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by regulating the JAK/STAT signaling pathway.
Song X; Ma J
Tissue Cell; 2022 Dec; 79():101954. PubMed ID: 36270072
[TBL] [Abstract][Full Text] [Related]
3. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
4. KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.
Li Y; Lv C; Yu Y; Wu B; Zhang Y; Lang Q; Liang Z; Zhong C; Shi Y; Han S; Xu F; Tian Y
J Adv Res; 2023 May; 47():137-150. PubMed ID: 35933091
[TBL] [Abstract][Full Text] [Related]
5. The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma.
Xiao Y; Li H; Yang LL; Mao L; Wu CC; Zhang WF; Sun ZJ
Dis Markers; 2019; 2019():5421985. PubMed ID: 31089395
[TBL] [Abstract][Full Text] [Related]
6. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.
Luo M; Xiong Y; Lin Y; Liang R; Li Y; Ge L
Med Sci Monit; 2021 May; 27():e930215. PubMed ID: 33990536
[TBL] [Abstract][Full Text] [Related]
7. EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling.
Liu ZK; Li C; Zhang RY; Wei D; Shang YK; Yong YL; Kong LM; Zheng NS; Liu K; Lu M; Liu M; Hu CX; Yang XZ; Chen ZN; Bian H
Mol Cancer; 2021 May; 20(1):79. PubMed ID: 34044846
[TBL] [Abstract][Full Text] [Related]
8. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
9. 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiates the anti-proliferative effect of interferon α/β by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells.
Wonganan O; He YJ; Shen XF; Wongkrajang K; Suksamrarn A; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2017 Dec; 336():31-39. PubMed ID: 29031523
[TBL] [Abstract][Full Text] [Related]
10. Exploring the JAK/STAT Signaling Pathway in Hepatocellular Carcinoma: Unraveling Signaling Complexity and Therapeutic Implications.
Park H; Lee S; Lee J; Moon H; Ro SW
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762066
[TBL] [Abstract][Full Text] [Related]
11. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
Wang R; Guo H; Tang X; Zhang T; Liu Y; Zhang C; Yu H; Li Y
Inflammation; 2022 Feb; 45(1):308-330. PubMed ID: 34536158
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-196a/-196b regulate the progression of hepatocellular carcinoma through modulating the JAK/STAT pathway via targeting SOCS2.
Ren W; Wu S; Wu Y; Liu T; Zhao X; Li Y
Cell Death Dis; 2019 Apr; 10(5):333. PubMed ID: 30988277
[TBL] [Abstract][Full Text] [Related]
13. Human cytokines activate JAK-STAT signaling pathway in porcine ocular tissue.
Fasler-Kan E; Barteneva NS; Ketterer S; Wunderlich K; Reschner A; Nurzhanova A; Flammer J; Huwyler J; Meyer P
Xenotransplantation; 2013; 20(6):469-80. PubMed ID: 24289470
[TBL] [Abstract][Full Text] [Related]
14. Potential of C1QTNF1-AS1 regulation in human hepatocellular carcinoma.
Han W; Yu G; Meng X; Hong H; Zheng L; Wu X; Zhang D; Yan B; Ma Y; Li X; Wang Q
Mol Cell Biochem; 2019 Oct; 460(1-2):37-51. PubMed ID: 31222560
[TBL] [Abstract][Full Text] [Related]
15. The Importance of HHLA2 in Solid Tumors-A Review of the Literature.
Kula A; Koszewska D; Kot A; Dawidowicz M; Mielcarska S; Waniczek D; Świętochowska E
Cells; 2024 May; 13(10):. PubMed ID: 38786018
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.
Ding L; Yu Q; Yang S; Yang WJ; Liu T; Xian JR; Tian TT; Li T; Chen W; Wang BL; Pan BS; Zhou J; Fan J; Yang XR; Guo W
Front Immunol; 2022; 13():831101. PubMed ID: 35371079
[TBL] [Abstract][Full Text] [Related]
17. HHLA2 immune-regulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Calvisi DF; Ladu S; Gorden A; Farina M; Conner EA; Lee JS; Factor VM; Thorgeirsson SS
Gastroenterology; 2006 Apr; 130(4):1117-28. PubMed ID: 16618406
[TBL] [Abstract][Full Text] [Related]
19. LINC00346 promotes hepatocellular carcinoma progression via activating the JAK-STAT3 signaling pathway.
Yin YZ; Zheng WH; Zhang X; Chen YH; Tuo YH
J Cell Biochem; 2020 Jan; 121(1):735-742. PubMed ID: 31478228
[TBL] [Abstract][Full Text] [Related]
20. JAK/STAT signaling and cellular iron metabolism in hepatocellular carcinoma: therapeutic implications.
Rah B; Farhat NM; Hamad M; Muhammad JS
Clin Exp Med; 2023 Nov; 23(7):3147-3157. PubMed ID: 36976378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
